131 related articles for article (PubMed ID: 15751501)
1. A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting.
Hesketh PJ; Aapro M; Jordan K; Schwartzberg L; Bosnjak S; Rugo H
Biomed Res Int; 2015; 2015():651879. PubMed ID: 26421300
[TBL] [Abstract][Full Text] [Related]
2. Acute chemotherapy-induced nausea and vomiting in children with cancer: Still waiting for a common consensus on treatment.
Ruggiero A; Rizzo D; Catalano M; Coccia P; Triarico S; Attiná G
J Int Med Res; 2018 Jun; 46(6):2149-2156. PubMed ID: 29690798
[TBL] [Abstract][Full Text] [Related]
3. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis.
Aogi K; Takeuchi H; Saeki T; Aiba K; Tamura K; Iino K; Imamura CK; Okita K; Kagami Y; Tanaka R; Nakagawa K; Fujii H; Boku N; Wada M; Akechi T; Iihara H; Ohtani S; Okuyama A; Ozawa K; Kim YI; Sasaki H; Shima Y; Takeda M; Nagasaki E; Nishidate T; Higashi T; Hirata K
Int J Clin Oncol; 2021 Jan; 26(1):1-17. PubMed ID: 33161452
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced nausea and vomiting: optimizing prevention and management.
Rao KV; Faso A
Am Health Drug Benefits; 2012 Jul; 5(4):232-40. PubMed ID: 24991322
[TBL] [Abstract][Full Text] [Related]
5. Inconsistency in steroid use as antiemetics in clinical trial protocols involving immune checkpoint inhibitors combined with chemotherapy.
Park SM; Kim YJ; Lee JY
Cancer Med; 2024 Apr; 13(7):e7142. PubMed ID: 38545845
[TBL] [Abstract][Full Text] [Related]
6. Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting.
Chrisp P
Core Evid; 2007 Mar; 2(1):15-30. PubMed ID: 21221195
[TBL] [Abstract][Full Text] [Related]
7. Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting.
Langford P; Chrisp P
Core Evid; 2010 Oct; 5():77-90. PubMed ID: 21042544
[TBL] [Abstract][Full Text] [Related]
8. Integrating aprepitant and palonosetron into clinical practice: a role for the new antiemetics.
Viale PH
Clin J Oncol Nurs; 2005 Feb; 9(1):77-84. PubMed ID: 15751501
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced nausea and vomiting: state of the art in 2006.
Schwartzberg L
J Support Oncol; 2006 Feb; 4(2 Suppl 1):3-8. PubMed ID: 16499138
[TBL] [Abstract][Full Text] [Related]
11. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
12. Update on the management of chemotherapy-induced nausea and vomiting.
Viale PH
J Infus Nurs; 2006; 29(5):283-92. PubMed ID: 17035890
[TBL] [Abstract][Full Text] [Related]
13. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting.
Oo TH; Hesketh PJ
Nat Clin Pract Oncol; 2005 Apr; 2(4):196-201. PubMed ID: 16264934
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
